Continue to meet or exceed healthcare partners’ expectations by providing on-time test results approximately 92 percent of the time.
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...